11,050 Shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Acquired by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. bought a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,050 shares of the specialty pharmaceutical company's stock, valued at approximately $1,372,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $25,000. Quadrant Capital Group LLC raised its position in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP raised its position in Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 183 shares during the period. CoreFirst Bank & Trust purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $28,000. Finally, Allianz SE purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $29,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JAZZ. Robert W. Baird cut their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Truist Financial boosted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Morgan Stanley cut their price objective on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $184.00.

Jazz Pharmaceuticals Stock Down 0.6%

JAZZ stock traded down $0.61 during mid-day trading on Friday, reaching $106.90. The company had a trading volume of 871,418 shares, compared to its average volume of 826,247. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. The company has a market capitalization of $6.47 billion, a price-to-earnings ratio of 14.25, a price-to-earnings-growth ratio of 4.61 and a beta of 0.33. The firm has a fifty day simple moving average of $108.63 and a 200 day simple moving average of $119.53. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same period in the prior year, the business earned $2.68 EPS. Jazz Pharmaceuticals's revenue for the quarter was down .5% on a year-over-year basis. Analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $107.90, for a total value of $53,950.00. Following the transaction, the chief executive officer now owns 438,473 shares in the company, valued at approximately $47,311,236.70. This represents a 0.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Seamus Mulligan acquired 100,000 shares of the company's stock in a transaction dated Friday, May 9th. The stock was acquired at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the acquisition, the director now owns 100,000 shares in the company, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 3,000 shares of company stock worth $355,925. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.